Stock Repurchase Program Authorized by AnaptysBio (NASDAQ:ANAB)

AnaptysBio (NASDAQ:ANAB) declared that its board has approved a stock buyback program on Friday, March 27th, RTT News reports. The company plans to buyback $100,000.00 billion in outstanding shares. This buyback authorization allows the biotechnology company to repurchase up to 5,352,316.2% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s board of directors believes its stock is undervalued.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on ANAB shares. Stifel Nicolaus raised their target price on AnaptysBio from $56.00 to $85.00 and gave the company a “buy” rating in a report on Thursday, March 5th. Truist Financial raised AnaptysBio to a “hold” rating in a report on Wednesday. Barclays raised their price objective on AnaptysBio from $78.00 to $79.00 and gave the company an “overweight” rating in a research note on Wednesday, March 4th. Wall Street Zen lowered AnaptysBio from a “strong-buy” rating to a “buy” rating in a report on Friday, January 23rd. Finally, Wedbush upped their target price on AnaptysBio from $60.00 to $75.00 and gave the stock an “outperform” rating in a research report on Thursday, March 12th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, AnaptysBio presently has a consensus rating of “Moderate Buy” and a consensus target price of $78.44.

AnaptysBio Price Performance

Shares of AnaptysBio stock opened at $57.40 on Friday. The company has a market cap of $1.65 billion, a PE ratio of -110.38 and a beta of 0.32. The firm has a fifty day moving average price of $55.30 and a two-hundred day moving average price of $43.64. AnaptysBio has a fifty-two week low of $15.40 and a fifty-two week high of $68.39.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings data on Tuesday, March 3rd. The biotechnology company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.89 by $0.69. AnaptysBio had a negative net margin of 5.64% and a negative return on equity of 1,101.24%. The company had revenue of $108.25 million for the quarter, compared to the consensus estimate of $87.09 million. Analysts expect that AnaptysBio will post -6.08 earnings per share for the current fiscal year.

Key Stories Impacting AnaptysBio

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: Analyst price target raised ~21% to $79.82, signaling stronger analyst expectations for the stock’s upside. Read More.
• Positive Sentiment: Truist upgraded the stock, reinforcing the bullish analyst view alongside the higher price target and potentially supporting future buying interest. Read More.
• Positive Sentiment: Board authorized a $100 million stock repurchase program — a capital-return move that typically reduces float and signals management’s view that shares are undervalued. Read More.
• Positive Sentiment: Board approved the previously announced spin‑off of First Tracks Biotherapeutics; the new company is expected to begin trading as TRAX on Nasdaq on April 20, 2026 — a structural change that can unlock value if investors assign separate valuations. Read More.
• Positive Sentiment: First Tracks secured commitments of $145 million in a private placement, which should fund the spin‑out’s initial operations and reduce execution risk for the new company. Read More.
• Neutral Sentiment: The company provided a business update alongside the repurchase/spin‑off announcements; details strengthen the strategic narrative but will be judged on execution. Read More.
• Negative Sentiment: CEO Daniel Faga sold 17,679 shares (≈$1.09M) at an average $61.61 on March 27, reducing his stake ~3.44%; insider sales can trigger investor caution and may have contributed to intraday selling pressure. Read More. Read More.

Insider Activity

In other AnaptysBio news, Director Magda Marquet sold 11,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $48.23, for a total value of $530,530.00. Following the completion of the sale, the director owned 9,930 shares in the company, valued at approximately $478,923.90. This trade represents a 52.56% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Daniel Faga sold 17,679 shares of AnaptysBio stock in a transaction that occurred on Friday, March 27th. The stock was sold at an average price of $61.61, for a total value of $1,089,203.19. Following the sale, the chief executive officer directly owned 495,965 shares in the company, valued at $30,556,403.65. The trade was a 3.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 110,193 shares of company stock valued at $5,333,138. Corporate insiders own 33.50% of the company’s stock.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.